Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -9% Improvement Relative Risk Progression 20% primary Hospitalization 17% c19early.org/e Eikelboom et al. NCT04324463 ACT outpatient Aspirin RCT LATE Favors aspirin Favors control
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00299-5, ACT outpatient, NCT04324463 (history)
10 Oct 2022    Source   PDF   Share   Tweet
Late (5.4 days) outpatient RCT showing no significant difference in outcomes with aspirin treatment.
risk of death, 9.0% higher, HR 1.09, p = 0.84, treatment 12 of 1,945 (0.6%), control 11 of 1,936 (0.6%).
risk of progression, 20.0% lower, HR 0.80, p = 0.21, treatment 59 of 1,945 (3.0%), control 73 of 1,936 (3.8%), NNT 136, major thrombosis, hospitalisation, or death, primary outcome.
risk of hospitalization, 17.0% lower, HR 0.83, p = 0.31, treatment 56 of 1,945 (2.9%), control 67 of 1,936 (3.5%), NNT 172.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Eikelboom et al., 10 Oct 2022, Randomized Controlled Trial, Canada, peer-reviewed, mean age 45.0, 31 authors, study period 27 August, 2020 - 10 February, 2022, average treatment delay 5.4 days, trial NCT04324463 (history) (ACT outpatient).
Contact: eikelbj@mcmaster.ca.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit